Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Current Deferred Tax Assets (2020 - 2024)

Historic Current Deferred Tax Assets for Vistagen Therapeutics (VTGN) over the last 5 years, with Q1 2024 value amounting to $74000.0.

  • Vistagen Therapeutics' Current Deferred Tax Assets rose 1044.78% to $74000.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $74000.0, marking a year-over-year increase of 1044.78%. This contributed to the annual value of $74000.0 for FY2024, which is 1044.78% up from last year.
  • Latest data reveals that Vistagen Therapeutics reported Current Deferred Tax Assets of $74000.0 as of Q1 2024, which was up 1044.78% from $74500.0 recorded in Q4 2023.
  • In the past 5 years, Vistagen Therapeutics' Current Deferred Tax Assets registered a high of $133500.0 during Q1 2021, and its lowest value of $67000.0 during Q3 2022.
  • Over the past 5 years, Vistagen Therapeutics' median Current Deferred Tax Assets value was $116900.0 (recorded in 2020), while the average stood at $99513.3.
  • As far as peak fluctuations go, Vistagen Therapeutics' Current Deferred Tax Assets soared by 1420.02% in 2021, and later crashed by 4981.27% in 2022.
  • Quarter analysis of 5 years shows Vistagen Therapeutics' Current Deferred Tax Assets stood at $116900.0 in 2020, then grew by 14.2% to $133500.0 in 2021, then plummeted by 49.81% to $67000.0 in 2022, then rose by 11.19% to $74500.0 in 2023, then dropped by 0.67% to $74000.0 in 2024.
  • Its last three reported values are $74000.0 in Q1 2024, $74500.0 for Q4 2023, and $74500.0 during Q3 2023.